On Jan. 9, 2024, GSK and Aiolos Bio, a clinical-stage biopharmaceutical company specializing in the treatment of respiratory and inflammatory conditions, announced that they have entered into an agreement for GSK to acquire Aiolos for $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments. Through the acquisition, GSK will gain access to Aiolos’ AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) that is ready to enter Phase II clinical development. Source: Biopharm International 9/1/2024